{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:52:39Z","timestamp":1790787159793,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41584-021-00706-y","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T10:18:43Z","timestamp":1633947523000},"page":"708-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Does psoriasis treatment affect PsA development?"],"prefix":"10.1038","volume":"17","author":[{"given":"Joseph F.","family":"Merola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"706_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher, J. U. et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat. Rev. Rheumatol. 15, 153\u2013166 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"706_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220865","author":"ML Acosta Felquer","year":"2021","unstructured":"Acosta Felquer, M. L. et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220865 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"706_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-219961","author":"P Gisondi","year":"2021","unstructured":"Gisondi, P. et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-219961 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"706_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/art.41946","author":"Y Shalev Rosenthal","year":"2021","unstructured":"Shalev Rosenthal, Y. et al. Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: a nested case control study. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41946 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"706_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11926-018-0785-6","volume":"20","author":"R Haberman","year":"2018","unstructured":"Haberman, R. et al. Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics. Curr. Rheumatol. Rep. 20, 76 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"706_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab622","author":"A Ogdie","year":"2021","unstructured":"Ogdie, A. et al. Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keab622 (2021).","journal-title":"Rheumatology"},{"key":"706_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s13075-021-02628-2","volume":"23","author":"A Ogdie","year":"2021","unstructured":"Ogdie, A. et al. Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis. Arthritis Res. Ther. 23, 252 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"706_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/annrheumdis-2017-211625","volume":"77","author":"U-SDT Nguyen","year":"2018","unstructured":"Nguyen, U.-S. D. T. et al. Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. Ann. Rheum. Dis. 77, 119\u2013123 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"706_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11926-020-00958-9","volume":"22","author":"S Bell","year":"2020","unstructured":"Bell, S. et al. Aiming for cure and preventive initiatives in psoriatic disease: building synergy at NPF, GRAPPA, and PPACMAN. Curr. Rheumatol. Rep. 22, 78 (2020).","journal-title":"Curr. Rheumatol. Rep."},{"key":"706_CR10","unstructured":"Hernan, M.A. & Robins, J. M. Causal Inference: What If (Boca Raton: Chapman & Hall, 2020)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00706-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:09:37Z","timestamp":1637539777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00706-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1038\/s41584-021-00706-y","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"11 October 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.F.M. declares he is a consultant and\/or investigator for Abbvie, Amgen, Biogen, BMS, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma and UCB. A.O. declares she has consulted for Abbvie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB and has received grants from Abbvie, Novartis and Pfizer to the University of Pennsylvania and Amgen to the Forward Databank. Her spouse has received royalties from Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}